Anti-MEFLIN antibody for use in treatment of cancer in subject having cancer, and pharmaceutical composition comprising the antibody

1 . An antibody that binds to MEFLIN, the antibody being selected from the group consisting of the following antibodies:

(1A) an antibody having

a heavy chain variable region comprising heavy chain CDR1 having the amino acid sequence set forth in SEQ ID NO: 1, heavy chain CDR2 having the amino acid sequence set forth in SEQ ID NO: 2, and heavy chain CDR3 having the amino acid sequence set forth in SEQ ID NO: 3, and

a light chain variable region comprising light chain CDR1 having the amino acid sequence set forth in SEQ ID NO: 4, light chain CDR2 having the amino acid sequence set forth in SEQ ID NO: 5, and light chain CDR3 having the amino acid sequence set forth in SEQ ID NO: 6;

(1B) an antibody having a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 7 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO: 8;

(2A) an antibody having

a heavy chain variable region comprising the heavy chain CDR1 set forth in SEQ ID NO: 9, the heavy chain CDR2 set forth in SEQ ID NO: 10, and the heavy chain CDR3 set forth in SEQ ID NO: 11, and

a light chain variable region comprising the light chain CDR1 set forth in SEQ ID NO: 12, the light chain CDR2 set forth in SEQ ID NO: 13, and the light chain CDR3 set forth in SEQ ID NO: 14;

(2B) an antibody having the heavy chain variable region set forth in SEQ ID NO: 15 and the light chain variable region set forth in SEQ ID NO: 16;

(3A) an antibody having

a heavy chain variable region comprising the heavy chain CDR1 set forth in SEQ ID NO: 17, the heavy chain CDR2 set forth in SEQ ID NO: 18, and the heavy chain CDR3 set forth in SEQ ID NO: 19, and

a light chain variable region comprising the light chain CDR1 set forth in SEQ ID NO: 20, the light chain CDR2 set forth in SEQ ID NO: 21, and the light chain CDR3 set forth in SEQ ID NO: 22;

(3B) an antibody having the heavy chain variable region set forth in SEQ ID NO: 23 and the light chain variable region set forth in SEQ ID NO: 24;

(4A) an antibody having

a heavy chain variable region comprising the heavy chain CDR1 set forth in SEQ ID NO: 25, the heavy chain CDR2 set forth in SEQ ID NO: 26, and the heavy chain CDR3 set forth in SEQ ID NO: 27, and

a light chain variable region comprising the light chain CDR1 set forth in SEQ ID NO: 28, the light chain CDR2 set forth in SEQ ID NO: 29, and the light chain CDR3 set forth in SEQ ID NO: 30;

(4B) an antibody having the heavy chain variable region set forth in SEQ ID NO: 31 and the light chain variable region set forth in SEQ ID NO: 32;

(5A) an antibody having

a heavy chain variable region comprising the heavy chain CDR1 set forth in SEQ ID NO: 33, the heavy chain CDR2 set forth in SEQ ID NO: 34, and the heavy chain CDR3 set forth in SEQ ID NO: 35, and

a light chain variable region comprising the light chain CDR1 set forth in SEQ ID NO: 36, the light chain CDR2 set forth in SEQ ID NO: 37, and the light chain CDR3 set forth in SEQ ID NO: 38;

(5B) an antibody having the heavy chain variable region set forth in SEQ ID NO: 39 and the light chain variable region set forth in SEQ ID NO: 40;

(6A) an antibody having

a heavy chain variable region comprising the heavy chain CDR1 set forth in SEQ ID NO: 41, the heavy chain CDR2 set forth in SEQ ID NO: 42, and the heavy chain CDR3 set forth in SEQ ID NO: 43, and

a light chain variable region comprising the light chain CDR1 set forth in SEQ ID NO: 44, the light chain CDR2 set forth in SEQ ID NO: 45, and the light chain CDR3 set forth in SEQ ID NO: 46;

(6B) an antibody having the heavy chain variable region set forth in SEQ ID NO: 47 and the light chain variable region set forth in SEQ ID NO: 48;

(7A) an antibody having

a heavy chain variable region comprising the heavy chain CDR1 set forth in SEQ ID NO: 57, the heavy chain CDR2 set forth in SEQ ID NO: 58, and the heavy chain CDR3 set forth in SEQ ID NO: 59, and

a light chain variable region comprising the light chain CDR1 set forth in SEQ ID NO: 60, the light chain CDR2 set forth in SEQ ID NO: 61, and the light chain CDR3 set forth in SEQ ID NO: 62;

(7B) an antibody having the heavy chain variable region set forth in SEQ ID NO: 63 and the light chain variable region set forth in SEQ ID NO: 64; and

(8A) an antibody having

a heavy chain variable region comprising the heavy chain CDR1 set forth in SEQ ID NO: 81, the heavy chain CDR2 set forth in SEQ ID NO: 82, and the heavy chain CDR3 set forth in SEQ ID NO: 83, and

a light chain variable region comprising the light chain CDR1 set forth in SEQ ID NO: 84, the light chain CDR2 set forth in SEQ ID NO: 85, and the light chain CDR3 set forth in SEQ ID NO: 86;

(8B) an antibody having the heavy chain variable region set forth in SEQ ID NO: 87 and the light chain variable region set forth in SEQ ID NO: 88.

2 . A pharmaceutical composition comprising an antibody-drug conjugate (ADC) of an antibody according to claim 1 and a cytotoxic agent.

3 . A method for treating a cancer in a subject, comprising administering to the subject the pharmaceutical composition of claim 2 .

4 . The method according to claim 3 , wherein the cancer is sarcoma.

5 . The method according to claim 4 , wherein the cancer is a MEFLIN-positive sarcoma.

6 . The method according to claim 4 , wherein the sarcoma is selected from the group consisting of myxofibrosarcoma, malignant fibrous histiocytoma, liposarcoma, leiomyosarcoma, rhabdomyosarcoma, neuroblastoma, malignant peripheral nerve sheath tumor, Ewing's sarcoma, epithelioid sarcoma, clear cell sarcoma, synovial sarcoma, and osteosarcoma.

7 . The method according to claim 3 , wherein the cancer is carcinoma.

8 . The method according to claim 3 , wherein the cancer is selected from the group consisting of breast cancer, pancreatic cancer, lung cancer, colorectal cancer, stomach cancer, bile duct cancer, ovary cancer, bladder cancer, and esophageal cancer.

9 . The method according to claim 3 , wherein the cancer is MEFLIN-negative, and a stroma surrounding the cancer contains MEFLIN-positive cells.

10 . The method according to claim 7 , wherein the antibody has no internalization activity.

11 . The method according to claim 4 , wherein the antibody has internalization activity.

12 . The method according to claim 10 , wherein the antibody and the cytotoxic agent of the ADC are connected to each other via a linker, and

wherein the linker is a cleavable linker.

13 . The method according to claim 12 , wherein the linker is cleaved by cathepsin K.

14 . The method according to claim 13 , wherein the linker comprises a valine-citrulline dipeptide and is cleaved in the presence of cathepsin K.

15 . The pharmaceutical composition according to claim 2 , wherein the antibody and the cytotoxic agent of the ADC are connected to each other via a linker, and wherein the linker is a non-cleavable linker.